Company Overview

The manufacturing and sale of proprietary ADAPT regenerative tissue products globally and continued research and development of regenerative medicine. Products under development in the aortic valve repair and replacement programme include DurAVRTM.

Directors and Management

Mr Stephen (Steve) Denaro

Company Secretary,Non-Executive Director 31/10/2018

Mr Denaro has more than 30 years of senior level and Board level experience across publicly-listed companies, serving as Chief Financial Officer, Company Secretary and Director. He brings experience in managing compliance with finance and accounting regulatory requirements. He has had manage investment acquisitions and subsequent funding (domestic and international). Mr Denaro has a interest in start-up companies. He is also a Non-Executive Director and Chair of the Audit & Risk Committee of a not-for-profit company, National Affordable Housing Consortium Limited. He is Chair of the Risk Management Committee.

BBus (Acc), CA, GDACG, MAICD, MCANZ&A, RTA Male

Mr John Seaberg

Non-Executive Director,Non-Executive Chairman 10/10/2014

Mr Seaberg has experience in cardiovascular products and markets. From 2008 until its sale to Baxter in 2012, Mr Seaberg served as Chairman of the Board of Synovis Inc. From 2007 until 2014 he was Founder, Chairman and CEO of NeoChord Inc. From 1996 to 2006, Mr Seaberg served at Guidant Corp where he served in range of executive level positions including Director of Bradycardia Marketing for Cardiac Rhythm Management, Vice President of Sales for Cardiac Surgery and Vice President of Sales for Cardiac Rhythm Management. In 1991, Mr Seaberg co-founded ACIST Medical and served as its first President and CEO. He was also the founder and CEO of Seaberg Medical. He is a member of the Risk Management Committee.

BA, MBA Male

Mr Wayne Paterson

Managing Director,Chief Executive Officer 09/02/2016

Mr Paterson has held range of senior positions in multinational pharmaceutical companies. Throughout his career, he has been in charge for building and managing businesses throughout the world, including; mergers, integrations, acquisitions and restructures as President and CEO. From 2005 to 2013 he held senior positions at Merck Kgaa, including President of Europe, Canada and Australia. Prior to this, Mr Paterson was President of markets, President of Japan and Global Head of Cardiovascular Medicine. Between 1999 and 2005, Mr Paterson served at Roche Pharmaceuticals where he was recently Head of Pharmaceuticals in Roche's South Korean operation. He also served as Head of Commercial Operations for Roche China based in Shanghai. He served as Non-Executive Director of Cepheid Inc from April 2015 to November 2016.

MBA, BBus, Business Course, INSEAD Male

Dr Wenyi Gu

Non-Executive Director 04/10/2018

Dr Gu currently works as a Research Fellow for the Australian Institute for Bioengineering and Nanotechnology at the University of Queensland where he began his postdoctoral work in 2001. Before engaging in nanomedicine, he worked on RNAibased gene therapy for years at Translational Research Institute. Dr Gu's research has been published in respected industry journals such as Nature Communications, Ad. Materials, ACS Nano and PNAS USA. He also held a Peter Doherty Fellowship (2006-2009) and was supported by the National Health and Medical Research Council to work at Harvard Medical School, Harvard University as a visiting fellow. He is a member of the Risk Management Committee.

MVSc, PhD(Biochem&Molecular Bio), PDF Male

Top 20 Shareholders

Director Transactions